Back to search

Aristotle University Of Thessaloniki (AUTH)

Ο ρόλος του παράγοντα αύξησης των ινοβλαστών (FGF-23) στη μεταβολική οστική νόσο των ασθενών με διαβητική νεφροπάθεια

Abstract

dc:description

Introduction: Fibroblast growth factor (FGF23) is a phosphatonin with an important role in the pathogenesis of many diseases characterized by renal phosphorus loss. Ιn early stages of renal disease - before hyperphosphataemia occurs - FGF23 retains its phosphaturic action. In end-stage CKD, FGF23 levels are very elevated (often 100-1000 times above normal) and correlate with high levels of phosphorus in the serum. Medical studies have focused on FGF23, as elevated levels of FGF23 have been positively correlated with atherosclerosis, endothelial dysfunction, cardiac morbidity and mortality. Purpose: The purpose of this study was to investigate fibroblast growth factor levels in patients with type 2 diabetic nephropathy and its association with biochemical markers of bone metabolism. Sample: For this purpose, a non-experimental case-control study was performed and involved 142 subjects (70 males and 72 females), 80 of whom had type 2 diabetes mellitus (D/M) and renal disease and 62 subjects the voluntary group of healthy subjects. Patients were assigned to the four stages of chronic renal disease (I-IV) and formed the first two groups, whereas the control group consisted of 31 patients with D/M 2 and normal renal function and 31 healthy patients without receiving any medication. The samples were selected from the Preventive Pathology Clinic of the AHEPA General Hospital. Procedure: All participants received a medical history and a clinical examination was performed. In particular, blood exams were recorded, biochemical examinations were performed, albuminuria was recorded, renal function was determined, and FGF23 levels were counted. Statistical analysis: The Kolmogorov-Smirnov test was used to investigate the data distribution. Because of the significant asymmetry in the data distribution for the analysis of the measurements, the non-parametric controls Kruskal-Wallis and Mann-Whitney were used to investigate between which groups there is a statistically significant difference. Results: Data analysis between the four groups for both FGF23 and bone metabolism markers showed that there was a statistically significant difference between the four groups in creatinine clearance (ClCr), calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), parathormone (PTH), Microalbuminuria (Microalb), 25(OH)D3 and 1.25(OH)2 D3. In addition, there was a statistically significant difference between the 4 groups in the FGF23 mean value. Conclusions: From the results of our study, it can be concluded that FGF23 was observed to increase early in stages I and II of diabetic renal disease and to reduce the production of 25(OH)D3 - an early biomarker of Diabetic Nephropathy. In addition FGF23 is linked to the early development of Diabetic Nephropathy, as well as the bone metabolism biomarkers of stages II, IV of Diabetic Nephropathy. Key words: Diabetic Nephropathy, Fibroblast growth factor 23 (FGF-23), Mineral Bone Disorder.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Myrou, Athina
  • Μύρου, Αθηνά

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44124

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Myrou, Athina; Μύρου, Αθηνά. Ο ρόλος του παράγοντα αύξησης των ινοβλαστών (FGF-23) στη μεταβολική οστική νόσο των ασθενών με διαβητική νεφροπάθεια. Aristotle University Of Thessaloniki (AUTH), 2018. http://hdl.handle.net/10442/hedi/44124